Caribou Biosciences (CRBU) Current Assets (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Current Assets data on file, last reported at $122.4 million in Q1 2026.

• Current Assets for Q1 2026 came in at $122.4 million, down 43.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $122.4 million (down 43.69% YoY), and the FY2025 annual result was $145.2 million, down 33.8% from the prior year.
• Current Assets declined to $122.4 million in Q1 2026 per CRBU's latest filing, from $145.2 million in the prior quarter.
• Over five years, Current Assets peaked at $368.0 million in Q1 2022 and troughed at $122.4 million in Q1 2026.
• A 5-year average of $255.9 million and a median of $260.2 million in 2022 frame the typical range for Current Assets.
• The sharpest annual moves came in 2022 and 2026: Current Assets jumped 146.86% in 2022, then slumped 43.69% in 2026.
• A 5-year view of Current Assets shows it stood at $260.2 million in 2022, then jumped by 30.2% to $338.8 million in 2023, then tumbled by 35.26% to $219.4 million in 2024, then tumbled by 33.8% to $145.2 million in 2025, then fell by 15.73% to $122.4 million in 2026.
• Business Quant data shows CRBU's Current Assets at $122.4 million in Q1 2026, $145.2 million in Q4 2025, and $155.5 million in Q3 2025.